Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101...
Q1 2026
May 14, 2026
FY 2025
Mar 10, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 6, 2025